2. Academic Validation
  3. A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation

A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation

  • Bioorg Chem. 2023 Dec:141:106901. doi: 10.1016/j.bioorg.2023.106901.
Digambar B Yevale 1,  Nishith Teraiya 2,  Twinkle D Lalwani 3,  Rakesh Kumar Ameta 4,  Chetan B Sangani 5
Affiliations

Affiliations

  • 1 Department of Chemistry, Shri M.M Patel Institute of Sciences and Research, Kadi Sarva Vishwavidyalaya, Gandhinagar 382016, Gujarat, India; Piramal Pharma Limited, Plot No. 18, Pharmaceutical Special Economic Zone, Village-Matoda, Taluka-Sanand, Ahmedabad 382213, Gujarat, India.
  • 2 Department of Pharmaceutical Chemistry, K B Institute of Pharmaceutical Education and Research, Kadi Sarva Vishvavidhyalay, Gandhinagar, Gujarat 382023, India.
  • 3 Piramal Pharma Limited, Plot No. 18, Pharmaceutical Special Economic Zone, Village-Matoda, Taluka-Sanand, Ahmedabad 382213, Gujarat, India.
  • 4 Department of Chemistry, Shri M.M Patel Institute of Sciences and Research, Kadi Sarva Vishwavidyalaya, Gandhinagar 382016, Gujarat, India.
  • 5 Department of Chemistry, Shri M.M Patel Institute of Sciences and Research, Kadi Sarva Vishwavidyalaya, Gandhinagar 382016, Gujarat, India; Department of Chemistry, Government Science College, Gujarat University, Gandhinagar 382016, Gujarat, India. Electronic address: [email protected].
PMID: 37797455 DOI: 10.1016/j.bioorg.2023.106901
Abstract

Pyrazole, as a small molecule, was discovered for higher cytotoxicity and affinity towards Aurora-A kinase. Based on these facts, a novel pyrazole substituted at the 4th position was designed, synthesized, and evaluated against MCF-7, MDA-MB-23, and Vero (non-cancerous kidney cell) cell lines. Compounds5hand5eexhibited greater cytotoxicity in the series against MCF-7 and MDA-MB-231, with GI50 values of 0.12 µM and 0.63 µM, respectively, as compared to Imatinib (GI50 values of 16.08 µM and 10.36 µM). All of the compounds displayed selective cytotoxicity against Cancer cells but not on normal Vero cells, supporting the design strategy to be a selective Anticancer agent. Furthermore, compounds 5h and 5e inhibited Aurora-A kinase with IC50 values of 0.78 µM (4.70-fold) and 1.12 µM (2.84-fold), respectively, as compared to alisertib (IC50 = 3.36 µM). In addition, compound 5h significantly arrested the cell cycle at G2/M (34.89 %, 5.56-fold) and the apoptotic phase (25.04 %, 11.81-fold) compared to the control. It also triggered an increase in early (7.43 %) and late (14.89 %) phase Apoptosis compared to vehicle (0.235 and 0.36 %, respectively), causing 37.89-fold higher total Apoptosis in the annexin-V assay. These data imply that Aurora-A kinase inhibition may be linked to Apoptosis induction and cell cycle arrest. Furthermore, their higher docking score in the study confirmed evidence of Aurora-kinase suppression. It was observed that fluorine and imidazole increased the H-bond and lipophilic interactions with the binding residue. Also, the substitution of electron-rich and lipophilic groups increased hydrophobic interactions. Moreover, the three-atom linkage (CH2NHCH2) expanded compound 5h to fill the cavity. Based on current findings, it is concluded that compounds 5h and 5e with strong Aurora-A kinase suppression may be promising Anticancer agents.

Keywords

Aurora-A kinase inhibitor; Molecular docking; Pyrazole; SRB assay.

Figures
Products